Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy...

Prof Chris Parker - Institute of Cancer Research, Sutton, UK

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma...

Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )

A new era of early cancer detection with blood test may change cancer screening ...

Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA

A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanc...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable he...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Pembro + CRT in HNSCC fails to deliver statistically significant event-free surv...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

Lenvatinib remains standard of care for first-line therapy in advanced hepatocel...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

New era of early cancer detection blood tests on the horizon

Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA

New era of early cancer detection blood tests on the horizon ( Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA )

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and...

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Franc...

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

Lasofoxifene shows promise for women with ESR1-mutated mBC

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Franc...

Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine t...

Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Net...

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy ( Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Netherlands )

Prognostic model of all-cause mortality at 30 days in patients with cancer and C...

Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19 ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer